000150530 001__ 150530
000150530 005__ 20260112133311.0
000150530 0247_ $$2doi$$a10.1007/s13346-024-01702-x
000150530 0248_ $$2sideral$$a142638
000150530 037__ $$aART-2024-142638
000150530 041__ $$aeng
000150530 100__ $$aAragón-Navas, Alba
000150530 245__ $$aMulti-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model
000150530 260__ $$c2024
000150530 5060_ $$aAccess copy available to the general public$$fUnrestricted
000150530 5203_ $$aThis work focused on the co-encapsulation and simultaneous co-delivery of three different neuroprotective drugs in PLGA (poly(lactic-co-glycolic acid) microspheres for the treatment of glaucoma. For formulation optimization, dexamethasone (anti-inflammatory) and ursodeoxycholic acid (anti-apoptotic) were co-loaded by the solid-in-oil-in-water emulsion solvent extraction-evaporation technique as a first step. The incorporation of a water-soluble co-solvent (ethanol) and different amounts of dexamethasone resulted critical for the encapsulation of the neuroprotective agents and their initial release. The optimized formulation was obtained with 60 mg of dexamethasone and using an 80:20 dichloromethane:ethanol ratio. In the second step in the microencapsulation process, the incorporation of the glial cell line-derived neurotrophic factor (GDNF) was performed. The final prototype showed encapsulation efficiencies for each component above 50% with suitable properties for long-term application for at least 3 months. Physicochemical studies were performed by SEM, TEM, DSC, XRD, and gas chromatography. The evaluation of the kinetic release by the Gallagher-Corrigan analysis with Gorrasi correction helped to understand the influence of the co-microencapsulation on the delivery of the different actives from the optimized formulation. The final prototype was tested in a chronic glaucoma animal model. Rats received two intravitreal injections of the neuroprotective treatment within a 24-week follow-up study. The proposed formulation improved retinal ganglion cell (RGC) functionality examined by electroretinography. Also, it was able to maintain a neuroretinal thickness similar to that of healthy animals scanned by in vivo optical coherence tomography, and a higher RGC count on histology compared to glaucomatous animals at the end of the study.
000150530 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-RETICS/RD16-0008-0004$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-RETICS/RD16-0008-0009$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-RETICS/RD16-0008-029$$9info:eu-repo/grantAgreement/ES/ISCIII/JR22-00057$$9info:eu-repo/grantAgreement/ES/MICINN/MAT2017-83858-C2-1$$9info:eu-repo/grantAgreement/ES/MICINN/MAT2017-83858-C2-2$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-113281RB-C21$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-113281RB-C22$$9info:eu-repo/grantAgreement/ES/MICINN/PRE2018-083951
000150530 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000150530 590__ $$a5.5$$b2024
000150530 592__ $$a1.175$$b2024
000150530 591__ $$aPHARMACOLOGY & PHARMACY$$b34 / 352 = 0.097$$c2024$$dQ1$$eT1
000150530 593__ $$aPharmaceutical Science$$c2024$$dQ1
000150530 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b41 / 195 = 0.21$$c2024$$dQ1$$eT1
000150530 594__ $$a12.7$$b2024
000150530 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000150530 700__ $$aRodrigo, Maria Jesus$$uUniversidad de Zaragoza
000150530 700__ $$aMunuera, Inés$$uUniversidad de Zaragoza
000150530 700__ $$aGarcía-Herranz, David
000150530 700__ $$aSubías, Manuel$$uUniversidad de Zaragoza
000150530 700__ $$aVillacampa, Pilar
000150530 700__ $$aGarcía-Feijoo, Julián
000150530 700__ $$0(orcid)0000-0003-2389-8282$$aPablo, Luis$$uUniversidad de Zaragoza
000150530 700__ $$0(orcid)0000-0001-6258-2489$$aGarcia-Martin, Elena$$uUniversidad de Zaragoza
000150530 700__ $$aHerrero-Vanrell, Rocio
000150530 700__ $$aBravo-Osuna, Irene
000150530 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000150530 773__ $$g15 (2024), 1660-1684$$pDrug deliv. transl. res.$$tDrug Delivery and Translational Research$$x2190-393X
000150530 8564_ $$s2548769$$uhttps://zaguan.unizar.es/record/150530/files/texto_completo.pdf$$yVersión publicada
000150530 8564_ $$s2332326$$uhttps://zaguan.unizar.es/record/150530/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000150530 909CO $$ooai:zaguan.unizar.es:150530$$particulos$$pdriver
000150530 951__ $$a2026-01-12-13:02:20
000150530 980__ $$aARTICLE